Phase II multi-institutional clinical trial on a new mixed beam RT scheme of IMRT on pelvis combined with a carbon ion boost for high-risk prostate cancer patients

Giulia Marvaso, Barbara Alicja Jereczek-Fossa, Barbara Vischioni, Delia Ciardo, Tommaso Giandini, Azusa Hasegawa, Federica Cattani, Mauro Carrara, Mario Ciocca, Nice Bedini, Sergio Villa, Sara Morlino, Stefania Russo, Dario Zerini, Sarah Pia Colangione, Costanza Maria Vittoria Panaino, Cristiana Fodor, Luigi Santoro, Emanuele Pignoli, Francesca Valvo & 3 others Riccardo Valdagni, Ottavio De Cobelli, Roberto Orecchia

Research output: Contribution to journalArticle

Abstract

PURPOSE: Definition of the optimal treatment schedule for high-risk prostate cancer is under debate. A combination of photon intensity modulated radiotherapy (IMRT) on pelvis with a carbon ion boost might be the optimal treatment scheme to escalate the dose on prostate and deliver curative dose with respect to normal tissue and quality of dose distributions. In fact, carbon ion beams offer the advantage to deliver hypofractionated radiotherapy (RT) using a significantly smaller number of fractions compared to conventional RT without increasing risks of late effects.

METHODS: This study is a prospective phase II clinical trial exploring safety and feasibility of a mixed beam scheme of carbon ion prostate boost followed by photon IMRT on pelvis. The study is designed to enroll 65 patients with localized high-risk prostate cancer at 3 different oncologic hospitals: Istituto Europeo di Oncologia, Fondazione IRCCS Istituto Nazionale dei Tumori, and Centro Nazionale di Adroterapia Oncologica. The primary endpoint is the evaluation of safety and feasibility with acute toxicity scored up to 1 month after the end of RT. Secondary endpoints are treatment early (3 months after the end of RT) and long-term tolerability, quality of life, and efficacy.

RESULTS: The study is not yet recruiting; in silico studies are ongoing and we expect to start recruitment by 2017.

CONCLUSIONS: The present clinical trial aims at improving the current treatment for high-risk prostate cancer, evaluating safety and feasibility of a new RT mixed-beam scheme including photons and carbon ions. Encouraging results are coming from carbon ion facilities worldwide on the treatment of different tumors including prostate cancers. Carbon ions combine physical properties allowing for high dose conformity and advantageous radiobiological characteristics. The proposed mixed beam treatment has the advantage to combine a photon high conformity standard of care IMRT phase with a hypofractionated carbon ion RT boost delivered in a short overall treatment time.

Original languageEnglish
Pages (from-to)0
JournalTumori
DOIs
Publication statusE-pub ahead of print - Dec 2 2016

Fingerprint

Intensity-Modulated Radiotherapy
Pelvis
Prostatic Neoplasms
Radiotherapy
Carbon
Clinical Trials
Ions
Photons
Safety
Therapeutics
Prostate
Heavy Ion Radiotherapy
Phase II Clinical Trials
Standard of Care
Computer Simulation
Appointments and Schedules
Quality of Life

Keywords

  • Journal Article

Cite this

Phase II multi-institutional clinical trial on a new mixed beam RT scheme of IMRT on pelvis combined with a carbon ion boost for high-risk prostate cancer patients. / Marvaso, Giulia; Jereczek-Fossa, Barbara Alicja; Vischioni, Barbara; Ciardo, Delia; Giandini, Tommaso; Hasegawa, Azusa; Cattani, Federica; Carrara, Mauro; Ciocca, Mario; Bedini, Nice; Villa, Sergio; Morlino, Sara; Russo, Stefania; Zerini, Dario; Colangione, Sarah Pia; Panaino, Costanza Maria Vittoria; Fodor, Cristiana; Santoro, Luigi; Pignoli, Emanuele; Valvo, Francesca; Valdagni, Riccardo; De Cobelli, Ottavio; Orecchia, Roberto.

In: Tumori, 02.12.2016, p. 0.

Research output: Contribution to journalArticle

Marvaso, Giulia ; Jereczek-Fossa, Barbara Alicja ; Vischioni, Barbara ; Ciardo, Delia ; Giandini, Tommaso ; Hasegawa, Azusa ; Cattani, Federica ; Carrara, Mauro ; Ciocca, Mario ; Bedini, Nice ; Villa, Sergio ; Morlino, Sara ; Russo, Stefania ; Zerini, Dario ; Colangione, Sarah Pia ; Panaino, Costanza Maria Vittoria ; Fodor, Cristiana ; Santoro, Luigi ; Pignoli, Emanuele ; Valvo, Francesca ; Valdagni, Riccardo ; De Cobelli, Ottavio ; Orecchia, Roberto. / Phase II multi-institutional clinical trial on a new mixed beam RT scheme of IMRT on pelvis combined with a carbon ion boost for high-risk prostate cancer patients. In: Tumori. 2016 ; pp. 0.
@article{cdb6f86df1f144ce9eff71e88761a1f4,
title = "Phase II multi-institutional clinical trial on a new mixed beam RT scheme of IMRT on pelvis combined with a carbon ion boost for high-risk prostate cancer patients",
abstract = "PURPOSE: Definition of the optimal treatment schedule for high-risk prostate cancer is under debate. A combination of photon intensity modulated radiotherapy (IMRT) on pelvis with a carbon ion boost might be the optimal treatment scheme to escalate the dose on prostate and deliver curative dose with respect to normal tissue and quality of dose distributions. In fact, carbon ion beams offer the advantage to deliver hypofractionated radiotherapy (RT) using a significantly smaller number of fractions compared to conventional RT without increasing risks of late effects.METHODS: This study is a prospective phase II clinical trial exploring safety and feasibility of a mixed beam scheme of carbon ion prostate boost followed by photon IMRT on pelvis. The study is designed to enroll 65 patients with localized high-risk prostate cancer at 3 different oncologic hospitals: Istituto Europeo di Oncologia, Fondazione IRCCS Istituto Nazionale dei Tumori, and Centro Nazionale di Adroterapia Oncologica. The primary endpoint is the evaluation of safety and feasibility with acute toxicity scored up to 1 month after the end of RT. Secondary endpoints are treatment early (3 months after the end of RT) and long-term tolerability, quality of life, and efficacy.RESULTS: The study is not yet recruiting; in silico studies are ongoing and we expect to start recruitment by 2017.CONCLUSIONS: The present clinical trial aims at improving the current treatment for high-risk prostate cancer, evaluating safety and feasibility of a new RT mixed-beam scheme including photons and carbon ions. Encouraging results are coming from carbon ion facilities worldwide on the treatment of different tumors including prostate cancers. Carbon ions combine physical properties allowing for high dose conformity and advantageous radiobiological characteristics. The proposed mixed beam treatment has the advantage to combine a photon high conformity standard of care IMRT phase with a hypofractionated carbon ion RT boost delivered in a short overall treatment time.",
keywords = "Journal Article",
author = "Giulia Marvaso and Jereczek-Fossa, {Barbara Alicja} and Barbara Vischioni and Delia Ciardo and Tommaso Giandini and Azusa Hasegawa and Federica Cattani and Mauro Carrara and Mario Ciocca and Nice Bedini and Sergio Villa and Sara Morlino and Stefania Russo and Dario Zerini and Colangione, {Sarah Pia} and Panaino, {Costanza Maria Vittoria} and Cristiana Fodor and Luigi Santoro and Emanuele Pignoli and Francesca Valvo and Riccardo Valdagni and {De Cobelli}, Ottavio and Roberto Orecchia",
year = "2016",
month = "12",
day = "2",
doi = "10.5301/tj.5000587",
language = "English",
pages = "0",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Phase II multi-institutional clinical trial on a new mixed beam RT scheme of IMRT on pelvis combined with a carbon ion boost for high-risk prostate cancer patients

AU - Marvaso, Giulia

AU - Jereczek-Fossa, Barbara Alicja

AU - Vischioni, Barbara

AU - Ciardo, Delia

AU - Giandini, Tommaso

AU - Hasegawa, Azusa

AU - Cattani, Federica

AU - Carrara, Mauro

AU - Ciocca, Mario

AU - Bedini, Nice

AU - Villa, Sergio

AU - Morlino, Sara

AU - Russo, Stefania

AU - Zerini, Dario

AU - Colangione, Sarah Pia

AU - Panaino, Costanza Maria Vittoria

AU - Fodor, Cristiana

AU - Santoro, Luigi

AU - Pignoli, Emanuele

AU - Valvo, Francesca

AU - Valdagni, Riccardo

AU - De Cobelli, Ottavio

AU - Orecchia, Roberto

PY - 2016/12/2

Y1 - 2016/12/2

N2 - PURPOSE: Definition of the optimal treatment schedule for high-risk prostate cancer is under debate. A combination of photon intensity modulated radiotherapy (IMRT) on pelvis with a carbon ion boost might be the optimal treatment scheme to escalate the dose on prostate and deliver curative dose with respect to normal tissue and quality of dose distributions. In fact, carbon ion beams offer the advantage to deliver hypofractionated radiotherapy (RT) using a significantly smaller number of fractions compared to conventional RT without increasing risks of late effects.METHODS: This study is a prospective phase II clinical trial exploring safety and feasibility of a mixed beam scheme of carbon ion prostate boost followed by photon IMRT on pelvis. The study is designed to enroll 65 patients with localized high-risk prostate cancer at 3 different oncologic hospitals: Istituto Europeo di Oncologia, Fondazione IRCCS Istituto Nazionale dei Tumori, and Centro Nazionale di Adroterapia Oncologica. The primary endpoint is the evaluation of safety and feasibility with acute toxicity scored up to 1 month after the end of RT. Secondary endpoints are treatment early (3 months after the end of RT) and long-term tolerability, quality of life, and efficacy.RESULTS: The study is not yet recruiting; in silico studies are ongoing and we expect to start recruitment by 2017.CONCLUSIONS: The present clinical trial aims at improving the current treatment for high-risk prostate cancer, evaluating safety and feasibility of a new RT mixed-beam scheme including photons and carbon ions. Encouraging results are coming from carbon ion facilities worldwide on the treatment of different tumors including prostate cancers. Carbon ions combine physical properties allowing for high dose conformity and advantageous radiobiological characteristics. The proposed mixed beam treatment has the advantage to combine a photon high conformity standard of care IMRT phase with a hypofractionated carbon ion RT boost delivered in a short overall treatment time.

AB - PURPOSE: Definition of the optimal treatment schedule for high-risk prostate cancer is under debate. A combination of photon intensity modulated radiotherapy (IMRT) on pelvis with a carbon ion boost might be the optimal treatment scheme to escalate the dose on prostate and deliver curative dose with respect to normal tissue and quality of dose distributions. In fact, carbon ion beams offer the advantage to deliver hypofractionated radiotherapy (RT) using a significantly smaller number of fractions compared to conventional RT without increasing risks of late effects.METHODS: This study is a prospective phase II clinical trial exploring safety and feasibility of a mixed beam scheme of carbon ion prostate boost followed by photon IMRT on pelvis. The study is designed to enroll 65 patients with localized high-risk prostate cancer at 3 different oncologic hospitals: Istituto Europeo di Oncologia, Fondazione IRCCS Istituto Nazionale dei Tumori, and Centro Nazionale di Adroterapia Oncologica. The primary endpoint is the evaluation of safety and feasibility with acute toxicity scored up to 1 month after the end of RT. Secondary endpoints are treatment early (3 months after the end of RT) and long-term tolerability, quality of life, and efficacy.RESULTS: The study is not yet recruiting; in silico studies are ongoing and we expect to start recruitment by 2017.CONCLUSIONS: The present clinical trial aims at improving the current treatment for high-risk prostate cancer, evaluating safety and feasibility of a new RT mixed-beam scheme including photons and carbon ions. Encouraging results are coming from carbon ion facilities worldwide on the treatment of different tumors including prostate cancers. Carbon ions combine physical properties allowing for high dose conformity and advantageous radiobiological characteristics. The proposed mixed beam treatment has the advantage to combine a photon high conformity standard of care IMRT phase with a hypofractionated carbon ion RT boost delivered in a short overall treatment time.

KW - Journal Article

U2 - 10.5301/tj.5000587

DO - 10.5301/tj.5000587

M3 - Article

SP - 0

JO - Tumori

JF - Tumori

SN - 0300-8916

ER -